Monopar Therapeutics (NASDAQ:MNPR) Stock Price Up 6.8% – Should You Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price traded up 6.8% during mid-day trading on Wednesday . The stock traded as high as $105.50 and last traded at $106.5640. Approximately 132,506 shares changed hands during mid-day trading, a decline of 37% from the average session volume of 210,256 shares. The stock had previously closed at $99.79.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $105.00 price objective on shares of Monopar Therapeutics in a research report on Monday, June 29th. BTIG Research lifted their target price on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Finally, Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Monopar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $108.75.

Monopar Therapeutics Stock Performance

The stock’s fifty day simple moving average is $72.95 and its 200-day simple moving average is $64.26. The stock has a market cap of $711.10 million, a P/E ratio of -55.86 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.41. As a group, equities research analysts forecast that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new stake in shares of Monopar Therapeutics during the 3rd quarter valued at $28,000. BNP Paribas Financial Markets increased its position in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $65,000. JPMorgan Chase & Co. raised its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics during the second quarter worth about $80,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.